News
FGEN
0.4393
+2.86%
0.0122
Catalyst Watch: Nvidia event could revive animal spirits, Fed meeting, and Nike earnings
Seeking Alpha · 2d ago
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at FGEN last week (0303-0307)?
Weekly Report · 6d ago
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Barchart · 03/03 15:45
Weekly Report: what happened at FGEN last week (0224-0228)?
Weekly Report · 03/03 09:08
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 02/27 12:10
FIBROGEN INC - ENTERED ATM EQUITY OFFERING SALES AGREEMENT RELATING TO SALE FROM TIME TO TIME OF SHARES OF COMMON STOCK
Reuters · 02/24 22:22
FIBROGEN- MAY OFFER, SELL SHARES OF COMMON STOCK FOR OFFERING PRICE OF UP TO $30.0 MLN FROM TIME TO TIME THROUGH BOFA
Reuters · 02/24 22:22
Weekly Report: what happened at FGEN last week (0217-0221)?
Weekly Report · 02/24 09:08
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise
Simply Wall St · 02/21 12:04
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
Benzinga · 02/20 18:08
FibroGen Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 02/20 17:13
FibroGen’s Strategic Sale and Pipeline Focus Justify Buy Rating Amid Financial Strength
TipRanks · 02/20 15:45
FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright
TipRanks · 02/20 15:40
BUZZ-U.S. STOCKS ON THE MOVE-Sabre, MicroStrategy, Repligen
Reuters · 02/20 15:38
Deals of the day-Mergers and acquisitions
Reuters · 02/20 14:41
FIBROGEN SHARES UP ABOUT 49% AFTER CO TO SELL CHINA UNIT TO ASTRAZENECA IN $160 MLN DEAL
Reuters · 02/20 14:35
M&A News: AstraZeneca Expands China Footprint With FibroGen Deal
TipRanks · 02/20 14:21
FibroGen Sells Subsidiary to AstraZeneca for $160M
TipRanks · 02/20 12:29
BUZZ-FibroGen soars on $160 mln China unit sale to AstraZeneca
Reuters · 02/20 12:06
More
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about Fibrogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
More
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.